Skip to main content

Peanut Allergy clinical trials at University of California Health

4 in progress, 2 open to eligible people

Showing trials for
  • Biologics to Improve Multi OIT Outcomes (COMBINE)

    open to eligible people ages 4-55

    Food allergy (FA) is a serious public health concern that causes potentially-life threatening reactions in affected patients. The prevalence of food allergy in the United States (U.S.) has increased substantially and now affects 15 million patients:4-8% of children (6 million children, 30% with multiple food allergies) and about 9% of adults. This is a prospective Phase 2, single-center, multi-allergen OIT study in participants with proven allergies to 2 or 3 different foods in which one must be a peanut. The total of participants in the clinical study will be 110, ages 4 to 55 years with a history of multiple food allergies of 2 to 3 different foods including peanut. Allergy will be confirmed by FA-specific IgE levels and positive skin prick test (SPT). Enrolled participants must be positive during the Double-blind Placebo-controlled Food challenge (DBPCFC) at or before the 300 mg (444 mg cumulative) dosing level of FA proteins.

    at UCLA UCSD

  • Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

    open to eligible people ages 4-7

    The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month treatment period.

    at UCLA

  • Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

    Sorry, accepting new patients by invitation only

    Open-label, follow-up study for subjects who completed the EPITOPE study.

    at UCLA UCSF

  • Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

    Sorry, in progress, not accepting new patients

    The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).

    at UCLA UCSD UCSF

Our lead scientists for Peanut Allergy research studies include .

Last updated: